30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Enanta Pharmaceuticals Inc (ENTA)

Track

The most recent insider trading activity occurred on December 5, 2025, with multiple executives selling shares. Notably, President and CEO Jay R. Luly sold shares valued at $67,492.89. Other officers also engaged in sales, totaling over $200,000 across several transactions on that date.
Stock chart
Ticker: ENTA Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Luly Jay R.
Officer; Director
2 sales — total 135,033 USD
Proposed sale 5 Dec 2025
Value US$1,788,048.23 | Price 327.75 | Shares 70,080
Sale 5 Dec 2025
Value US$3,923,021.59 | Price 120.36 | Shares 75,522
Sale 5 Dec 2025
Value US$2,520,075.71 | Price 97.95 | Shares 6,497
Sale 5 Dec 2025
Value US$7,712.66 | Price 14.23 | Shares 542
Sale 5 Dec 2025
Value US$4,596.29 | Price 14.23 | Shares 323
Sale 5 Dec 2025
Value US$29,968.38 | Price 14.23 | Shares 2,106
Sale 5 Dec 2025
Value US$34,009.70 | Price 14.23 | Shares 2,390
Sale 5 Dec 2025
Value US$11,355.54 | Price 14.23 | Shares 798
Sale 2 Dec 2025
Value US$5,304.80 | Price 13.96 | Shares 380
Sale 2 Dec 2025
Value US$2,889.72 | Price 13.96 | Shares 207
Buy 12 Feb 2025
Value US$256,050.00 | Price 5.69 | Shares 45,000
Sale 6 Dec 2024
Value US$18,400.98 | Price 8.06 | Shares 2,283
Sale 6 Dec 2024
Value US$20,883.46 | Price 8.06 | Shares 2,591
Sale 6 Dec 2024
Value US$18,400.98 | Price 8.06 | Shares 2,283
Sale 6 Dec 2024
Value US$6,979.96 | Price 8.06 | Shares 866
Sale 6 Dec 2024
Value US$20,883.46 | Price 8.06 | Shares 2,591
Sale 6 Dec 2024
Value US$41,444.52 | Price 8.06 | Shares 5,142
Planned sale 15 Jul 2024
Value US$91,805.00 | Price 17.08 | Shares 5,375
Planned sale 12 Jul 2024
Value US$34,155.84 | Price 15.04 | Shares 2,271
Planned sale 11 Jul 2024
Value US$64,785.93 | Price 15.07 | Shares 4,299
Proposed sale 11 Jul 2024
Value US$178,697.00 | Price 14.96 | Shares 11,945
Proposed sale 17 Jun 2024
Value US$92,351.00 | Price 12.71 | Shares 7,266
Planned sale 17 Jun 2024
Value US$89,589.78 | Price 12.33 | Shares 7,266
Sale 13 Dec 2023
Value US$139,490.40 | Price 9.12 | Shares 15,295
Proposed sale 13 Dec 2023
Value US$138,572.70 | Price 9.06 | Shares 15,295
Sale 5 Dec 2023
Value US$20,463.75 | Price 9.63 | Shares 2,125
Sale 5 Dec 2023
Value US$23,227.56 | Price 9.63 | Shares 2,412
Sale 5 Dec 2023
Value US$23,227.56 | Price 9.63 | Shares 2,412
Sale 5 Dec 2023
Value US$20,463.75 | Price 9.63 | Shares 2,125
Sale 5 Dec 2023
Value US$5,142.42 | Price 9.63 | Shares 534
Sale 5 Dec 2023
Value US$69,624.90 | Price 9.63 | Shares 7,230
Sale 5 Dec 2023
Value US$23,227.56 | Price 9.63 | Shares 2,412
Planned sale 15 Mar 2023
Value US$459,406.20 | Price 44.43 | Shares 10,340
Planned sale 15 Mar 2023
Value US$4,396.00 | Price 43.96 | Shares 100
Planned sale 15 Mar 2023
Value US$607,145.76 | Price 44.46 | Shares 13,656
Planned sale 15 Mar 2023
Value US$11,814.48 | Price 43.92 | Shares 269
Planned sale 13 Mar 2023
Value US$72,239.58 | Price 46.13 | Shares 1,566
Planned sale 13 Mar 2023
Value US$709,056.19 | Price 45.31 | Shares 15,649
Planned sale 13 Mar 2023
Value US$479,332.57 | Price 44.81 | Shares 10,697
Planned sale 9 Feb 2023
Value US$43,528.00 | Price 54.41 | Shares 800
Planned sale 9 Feb 2023
Value US$225,288.00 | Price 53.64 | Shares 4,200
Planned sale 16 Dec 2022
Value US$618,800.47 | Price 45.49 | Shares 13,603
Planned sale 16 Dec 2022
Value US$382,910.38 | Price 44.54 | Shares 8,597
Planned sale 16 Dec 2022
Value US$340,002.00 | Price 43.59 | Shares 7,800
Planned sale 4 Apr 2022
Value US$661,440.78 | Price 73.42 | Shares 9,009
Planned sale 4 Apr 2022
Value US$232,480.00 | Price 72.65 | Shares 3,200
Planned sale 4 Apr 2022
Value US$1,296,229.96 | Price 71.71 | Shares 18,076
Planned sale 4 Apr 2022
Value US$176,400.00 | Price 70.56 | Shares 2,500
Planned sale 1 Apr 2022
Value US$3,013,983.20 | Price 71.32 | Shares 42,260
Planned sale 1 Apr 2022
Value US$587,154.25 | Price 70.75 | Shares 8,299
Planned sale 21 Mar 2022
Value US$56,102.64 | Price 69.52 | Shares 807
Planned sale 21 Mar 2022
Value US$151,738.60 | Price 68.66 | Shares 2,210
Planned sale 21 Mar 2022
Value US$20,639.61 | Price 67.23 | Shares 307
Planned sale 21 Mar 2022
Value US$178,489.20 | Price 66.70 | Shares 2,676
Planned sale 2 Mar 2022
Value US$874,543.67 | Price 70.07 | Shares 12,481
Planned sale 1 Mar 2022
Value US$7,106.00 | Price 71.06 | Shares 100
Planned sale 1 Mar 2022
Value US$1,703,032.14 | Price 70.26 | Shares 24,239
Planned sale 11 Jan 2022
Value US$879,149.68 | Price 70.13 | Shares 12,536
Planned sale 1 Dec 2021
Value US$18,124.17 | Price 90.17 | Shares 201
Planned sale 1 Dec 2021
Value US$80,307.67 | Price 89.33 | Shares 899
Planned sale 1 Dec 2021
Value US$79,479.00 | Price 88.31 | Shares 900
Planned sale 1 Dec 2021
Value US$131,400.00 | Price 87.60 | Shares 1,500
Planned sale 1 Dec 2021
Value US$233,415.00 | Price 86.45 | Shares 2,700
Planned sale 1 Dec 2021
Value US$490,370.64 | Price 85.49 | Shares 5,736
Planned sale 1 Dec 2021
Value US$134,593.47 | Price 84.81 | Shares 1,587
Planned sale 1 Nov 2021
Value US$8,621.00 | Price 86.21 | Shares 100
Planned sale 1 Nov 2021
Value US$637,224.90 | Price 85.02 | Shares 7,495
Planned sale 1 Nov 2021
Value US$164,573.12 | Price 84.31 | Shares 1,952
Planned sale 11 Oct 2021
Value US$284,685.41 | Price 70.34 | Shares 4,047
Planned sale 8 Oct 2021
Value US$942,934.22 | Price 70.09 | Shares 13,453
Planned sale 15 Sep 2021
Value US$266,697.80 | Price 59.06 | Shares 4,516
Planned sale 8 Jan 2021
Value US$273,462.60 | Price 45.58 | Shares 6,000
Planned sale 2 Jan 2020
Value US$44,458.23 | Price 61.66 | Shares 721
Planned sale 2 Jan 2020
Value US$564,341.36 | Price 60.82 | Shares 9,279
Planned sale 11 Mar 2019
Value US$153,301.36 | Price 99.16 | Shares 1,546
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-12-05 2025-12-05 PrS Proposed sale
3.1
Luly Jay R.

Officer; Director

Executive Director
70,080
327.75
US$1,788,048 		70,080 327.75 US$1,788,048
2025-12-05 2025-12-05 S Sale
2.5
Luu Brendan

Chief Business Officer

Officer
6,497 +23.3%
97.95
US$2,520,076 		6,497 +23.3% 97.95 US$2,520,076
2025-12-05 2025-12-05 S Sale
2.5
Trout Harry R. III

See Remarks

Officer
18,899 +2.7%
409.85
US$1,088,143 		18,899 +2.7% 409.85 US$1,088,143
2025-12-05 2025-12-05 S Sale
2.6
Capps Kathleen S.

See Remarks

Officer
323 -3.7%
14.23
US$4,596 		323 -3.7% 14.23 US$4,596
2025-12-05 2025-12-05 S Sale
2.6
Kieffer Tara Lynn

Chief Product Strategy Officer

Officer
2,106 -6.4%
14.23
US$29,968 		2,106 -6.4% 14.23 US$29,968
2025-12-05 2025-12-05 S Sale
2.6
Or Yat Sun

Chief Scientific Officer

Officer
2,390 -0.6%
14.23
US$34,010 		2,390 -0.6% 14.23 US$34,010
2025-12-05 2025-12-05 S Sale
2.9
Rottinghaus Scott T.

Chief Medical Officer

Officer
798 -3.5%
14.23
US$11,356 		798 -3.5% 14.23 US$11,356
2025-12-05 2025-12-05 S Sale
3.1
Luly Jay R.

President and CEO

Executive Director
4,743 -0.5%
14.23
US$67,493 		4,743 -0.5% 14.23 US$67,493
2025-12-03 2025-12-02 S Sale
2.5
Trout Harry R. III

See Remarks

Officer
380 -2.2%
13.96
US$5,305 		380 -2.2% 13.96 US$5,305
2025-12-03 2025-12-02 S Sale
2.6
Capps Kathleen S.

See Remarks

Officer
207 -2.3%
13.96
US$2,890 		207 -2.3% 13.96 US$2,890
2025-02-12 2025-02-12 B Purchase
3.1
Luly Jay R.

President and CEO

Executive Director
45,000 +5.6%
5.69
US$256,050 		45,000 +5.6% 5.69 US$256,050
2024-12-10 2024-12-06 S Sale
2.6
Kieffer Tara Lynn

Chief Product Strategy Officer

Officer
2,283 -7.2%
8.06
US$18,401 		2,283 -7.2% 8.06 US$18,401
2024-12-10 2024-12-06 S Sale
2.6
Or Yat Sun

Chief Scientific Officer

Officer
2,591 -0.7%
8.06
US$20,883 		2,591 -0.7% 8.06 US$20,883
2024-12-10 2024-12-06 S Sale
2.5
Luu Brendan

Chief Business Officer

Officer
2,283 -6.0%
8.06
US$18,401 		2,283 -6.0% 8.06 US$18,401
2024-12-10 2024-12-06 S Sale
2.9
Rottinghaus Scott T.

Chief Medical Officer

Officer
866 -4.6%
8.06
US$6,980 		866 -4.6% 8.06 US$6,980
2024-12-10 2024-12-06 S Sale
1.9
MELLETT PAUL J

Chief Fin. & Admin Officer

Officer
2,591 -2.7%
8.06
US$20,883 		2,591 -2.7% 8.06 US$20,883
2024-12-10 2024-12-06 S Sale
3.1
Luly Jay R.

President and CEO

Executive Director
5,142 -0.6%
8.06
US$41,445 		5,142 -0.6% 8.06 US$41,445
2024-07-15 2024-07-15 PlS Planned sale
2.9
Rottinghaus Scott T.

Chief Medical Officer

Officer
5,375 -19.8%
17.08
US$91,805 		5,375 -19.8% 17.08 US$91,805
2024-07-15 2024-07-12 PlS Planned sale
2.9
Rottinghaus Scott T.

Chief Medical Officer

Officer
2,271 -9.5%
15.04
US$34,156 		2,271 -9.5% 15.04 US$34,156
2024-07-15 2024-07-11 PlS Planned sale
2.9
Rottinghaus Scott T.

Chief Medical Officer

Officer
4,299 -15.2%
15.07
US$64,786 		4,299 -15.2% 15.07 US$64,786
2024-07-11 2024-07-11 PrS Proposed sale
2.9
Scott T. Rottinghaus

Officer

Officer
11,945
14.96
US$178,697 		11,945 14.96 US$178,697
2024-06-17 2024-06-17 PrS Proposed sale
2.6
Tara Lynn Kieffer

Officer

Officer
7,266
12.71
US$92,351 		7,266 12.71 US$92,351
2024-06-17 2024-06-17 PlS Planned sale
2.6
Kieffer Tara Lynn

Chief Product Strategy Officer

Officer
7,266 -18.3%
12.33
US$89,590 		7,266 -18.3% 12.33 US$89,590
2023-12-15 2023-12-13 S Sale
0.5
Vance Terry
Non-Executive Director
15,295 -72.5%
9.12
US$139,490 		15,295 -72.5% 9.12 US$139,490
2023-12-12 2023-12-13 PrS Proposed sale
0.5
Vance Terry

Director

Non-Executive Director
15,295
9.06
US$138,573 		15,295 9.06 US$138,573
2023-12-06 2023-12-05 S Sale
2.6
Kieffer Tara Lynn

Sr. VP, New Prod. Strat. & Dev

Officer
2,125 -5.4%
9.63
US$20,464 		2,125 -5.4% 9.63 US$20,464
2023-12-06 2023-12-05 S Sale
1.9
MELLETT PAUL J

Sr. VP, Finance & Admin. & CFO

Officer
2,412 -2.5%
9.63
US$23,228 		2,412 -2.5% 9.63 US$23,228
2023-12-06 2023-12-05 S Sale
2.6
Or Yat Sun

Sr. VP, R&D & CSO

Officer
2,412 -0.6%
9.63
US$23,228 		2,412 -0.6% 9.63 US$23,228
2023-12-06 2023-12-05 S Sale
2.5
Luu Brendan

Sr. VP, Business Dev.

Officer
2,125 -5.5%
9.63
US$20,464 		2,125 -5.5% 9.63 US$20,464
2023-12-06 2023-12-05 S Sale
2.9
Rottinghaus Scott T.

Sr. VP & CMO

Officer
534 -2.0%
9.63
US$5,142 		534 -2.0% 9.63 US$5,142
2023-12-06 2023-12-05 S Sale
3.1
Luly Jay R.

President and CEO

Executive Director
7,230 -0.9%
9.63
US$69,625 		7,230 -0.9% 9.63 US$69,625
2023-12-06 2023-12-05 S Sale
0.5
Gardiner Nathaniel S.

Sr. VP & General Counsel

Officer
2,412 -3.4%
9.63
US$23,228 		2,412 -3.4% 9.63 US$23,228
2023-03-17 2023-03-15 PlS Planned sale
1.9
MELLETT PAUL J

Treasurer and CFO

Officer
10,340 -9.6%
44.43
US$459,406 		10,340 -9.6% 44.43 US$459,406
2023-03-17 2023-03-15 PlS Planned sale
1.9
MELLETT PAUL J

Treasurer and CFO

Officer
100 -0.1%
43.96
US$4,396 		100 -0.1% 43.96 US$4,396
2023-03-17 2023-03-15 PlS Planned sale
2.6
Or Yat Sun

Sr. VP & CSO

Officer
13,656 -3.5%
44.46
US$607,146 		13,656 -3.5% 44.46 US$607,146
2023-03-17 2023-03-15 PlS Planned sale
2.6
Or Yat Sun

Sr. VP & CSO

Officer
269 -0.1%
43.92
US$11,814 		269 -0.1% 43.92 US$11,814
2023-03-14 2023-03-13 PlS Planned sale
3.1
Luly Jay R.

President and CEO

Executive Director
1,566 -0.2%
46.13
US$72,240 		1,566 -0.2% 46.13 US$72,240
2023-03-14 2023-03-13 PlS Planned sale
3.1
Luly Jay R.

President and CEO

Executive Director
15,649 -1.9%
45.31
US$709,056 		15,649 -1.9% 45.31 US$709,056
2023-03-14 2023-03-13 PlS Planned sale
3.1
Luly Jay R.

President and CEO

Executive Director
10,697 -1.3%
44.81
US$479,333 		10,697 -1.3% 44.81 US$479,333
2023-02-13 2023-02-09 PlS Planned sale
1.9
MELLETT PAUL J

Treasurer and CFO

Officer
800 -0.9%
54.41
US$43,528 		800 -0.9% 54.41 US$43,528
2023-02-13 2023-02-09 PlS Planned sale
1.9
MELLETT PAUL J

Treasurer and CFO

Officer
4,200 -4.7%
53.64
US$225,288 		4,200 -4.7% 53.64 US$225,288
2022-12-16 2022-12-16 PlS Planned sale
3.1
Luly Jay R.

President and CEO

Executive Director
13,603 -1.7%
45.49
US$618,800 		13,603 -1.7% 45.49 US$618,800
2022-12-16 2022-12-16 PlS Planned sale
3.1
Luly Jay R.

President and CEO

Executive Director
8,597 -1.1%
44.54
US$382,910 		8,597 -1.1% 44.54 US$382,910
2022-12-16 2022-12-16 PlS Planned sale
3.1
Luly Jay R.

President and CEO

Executive Director
7,800 -1.0%
43.59
US$340,002 		7,800 -1.0% 43.59 US$340,002
2022-04-05 2022-04-04 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
9,009 -20.5%
73.42
US$661,441 		9,009 -20.5% 73.42 US$661,441
2022-04-05 2022-04-04 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
3,200 -6.8%
72.65
US$232,480 		3,200 -6.8% 72.65 US$232,480
2022-04-05 2022-04-04 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
18,076 -27.7%
71.71
US$1,296,230 		18,076 -27.7% 71.71 US$1,296,230
2022-04-05 2022-04-04 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
2,500 -3.7%
70.56
US$176,400 		2,500 -3.7% 70.56 US$176,400
2022-04-05 2022-04-01 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
42,260 -54.7%
71.32
US$3,013,983 		42,260 -54.7% 71.32 US$3,013,983
2022-04-05 2022-04-01 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
8,299 -9.7%
70.75
US$587,154 		8,299 -9.7% 70.75 US$587,154
2022-03-22 2022-03-21 PlS Planned sale
2.6
CARTER BRUCE L A
Non-Executive Director
807 -100.0%
69.52
US$56,103 		807 -100.0% 69.52 US$56,103
2022-03-22 2022-03-21 PlS Planned sale
2.6
CARTER BRUCE L A
Non-Executive Director
2,210 -73.3%
68.66
US$151,739 		2,210 -73.3% 68.66 US$151,739
2022-03-22 2022-03-21 PlS Planned sale
2.6
CARTER BRUCE L A
Non-Executive Director
307 -9.2%
67.23
US$20,640 		307 -9.2% 67.23 US$20,640
2022-03-22 2022-03-21 PlS Planned sale
2.6
CARTER BRUCE L A
Non-Executive Director
2,676 -44.6%
66.70
US$178,489 		2,676 -44.6% 66.70 US$178,489
2022-03-03 2022-03-02 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
12,481 -26.3%
70.07
US$874,544 		12,481 -26.3% 70.07 US$874,544
2022-03-03 2022-03-01 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
100 -0.3%
71.06
US$7,106 		100 -0.3% 71.06 US$7,106
2022-03-03 2022-03-01 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
24,239 -40.9%
70.26
US$1,703,032 		24,239 -40.9% 70.26 US$1,703,032
2022-01-13 2022-01-11 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
12,536 -27.6%
70.13
US$879,150 		12,536 -27.6% 70.13 US$879,150
2021-12-03 2021-12-01 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
201 -0.6%
90.17
US$18,124 		201 -0.6% 90.17 US$18,124
2021-12-03 2021-12-01 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
899 -2.6%
89.33
US$80,308 		899 -2.6% 89.33 US$80,308
2021-12-03 2021-12-01 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
900 -2.6%
88.31
US$79,479 		900 -2.6% 88.31 US$79,479
2021-12-03 2021-12-01 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
1,500 -4.1%
87.60
US$131,400 		1,500 -4.1% 87.60 US$131,400
2021-12-03 2021-12-01 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
2,700 -6.9%
86.45
US$233,415 		2,700 -6.9% 86.45 US$233,415
2021-12-03 2021-12-01 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
5,736 -12.8%
85.49
US$490,371 		5,736 -12.8% 85.49 US$490,371
2021-12-03 2021-12-01 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
1,587 -3.4%
84.81
US$134,593 		1,587 -3.4% 84.81 US$134,593
2021-11-02 2021-11-01 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
100 -0.4%
86.21
US$8,621 		100 -0.4% 86.21 US$8,621
2021-11-02 2021-11-01 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
7,495 -21.7%
85.02
US$637,225 		7,495 -21.7% 85.02 US$637,225
2021-11-02 2021-11-01 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
1,952 -5.3%
84.31
US$164,573 		1,952 -5.3% 84.31 US$164,573
2021-10-13 2021-10-11 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
4,047 -13.1%
70.34
US$284,685 		4,047 -13.1% 70.34 US$284,685
2021-10-13 2021-10-08 PlS Planned sale
Adda Nathalie

Sr. VP & Chief Medical Officer

Officer
13,453 -33.3%
70.09
US$942,934 		13,453 -33.3% 70.09 US$942,934
2021-09-17 2021-09-15 PlS Planned sale
3.1
Luly Jay R.

President and CEO

Executive Director
4,516 -0.7%
59.06
US$266,698 		4,516 -0.7% 59.06 US$266,698
2021-01-08 2021-01-08 PlS Planned sale
1.9
MELLETT PAUL J

Treasurer and CFO

Officer
6,000 -8.9%
45.58
US$273,463 		6,000 -8.9% 45.58 US$273,463
2020-01-06 2020-01-02 PlS Planned sale
1.9
MELLETT PAUL J

Treasurer and CFO

Officer
721 -1.8%
61.66
US$44,458 		721 -1.8% 61.66 US$44,458
2020-01-06 2020-01-02 PlS Planned sale
1.9
MELLETT PAUL J

Treasurer and CFO

Officer
9,279 -18.5%
60.82
US$564,341 		9,279 -18.5% 60.82 US$564,341
2019-03-12 2019-03-11 PlS Planned sale
2.6
CARTER BRUCE L A
1,546 -100.0%
99.16
US$153,301 		1,546 -100.0% 99.16 US$153,301
Explore more

More insider trading research around Enanta Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America